Terms: = Colorectal cancer AND PTEN, MMAC1, 5728, MGC11227, PTEN1, MHAM, P60484, BZS, ENSG00000171862 AND Treatment
291 results:
1. Specific and efficient knockdown of intracellular miRNA using partially neutralized phosphate-methylated DNA oligonucleic acid-loaded mesoporous silica nanoparticles.
Sung YJ; Cai WT; Chen YP; Chan HW; Lin CK; Wang PH; Chen WY
J Mater Chem B; 2024 Jul; 12(26):6492-6499. PubMed ID: 38872610
[TBL] [Abstract] [Full Text] [Related]
2. pten and P-4E-BP1 might be associated with postoperative recurrence of rectal cancer patients undergoing concurrent radiochemotherapy.
Zhang H; Li X; Sun W; Qin H; Li H; Yan H; Wang H; Zhang X; Zhang S; Wang H
BMC Cancer; 2024 May; 24(1):582. PubMed ID: 38741069
[TBL] [Abstract] [Full Text] [Related]
3. SNHG4-mediated pten destabilization confers oxaliplatin resistance in colorectal cancer cells by inhibiting ferroptosis.
Li SQ; Xu WT; Yin YX; Wei HT; Li KZ; Xie MZ; Lv F; Xie LY; Hu BL
Apoptosis; 2024 Jun; 29(5-6):835-848. PubMed ID: 38573492
[TBL] [Abstract] [Full Text] [Related]
4. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
Shitara K; Muro K; Watanabe J; Yamazaki K; Ohori H; Shiozawa M; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Mori I; Yamanaka K; Hihara M; Soeda J; Misumi T; Yamamoto K; Yamashita R; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
Nat Med; 2024 Mar; 30(3):730-739. PubMed ID: 38347302
[TBL] [Abstract] [Full Text] [Related]
5. Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic colorectal cancer (PanaMa Phase II Trial, AIO KRK 0212).
Stahler A; Kind AJ; Sers C; Mamlouk S; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Sommerhäuser G; Kasper S; Hoppe B; Kurreck A; Held S; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
Clin Cancer Res; 2024 Apr; 30(7):1256-1263. PubMed ID: 38289994
[TBL] [Abstract] [Full Text] [Related]
6.
Battaglin F; Baca Y; Millstein J; Yang Y; Xiu J; Arai H; Wang J; Ou FS; Innocenti F; Mumenthaler SM; Jayachandran P; Kawanishi N; Lenz A; Soni S; Algaze S; Zhang W; Khoukaz T; Roussos Torres E; Seeber A; Abraham JP; Lou E; Philip PA; Weinberg BA; Shields AF; Goldberg RM; Marshall JL; Venook AP; Korn WM; Lenz HJ
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212126
[TBL] [Abstract] [Full Text] [Related]
7. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
[TBL] [Abstract] [Full Text] [Related]
9. Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
Pietrantonio F; Bergamo F; Rossini D; Ghelardi F; De Grandis MC; Germani MM; Barsotti G; Formica V; Frassineti GL; Boscolo G; Cinieri S; Di Donato S; Antonuzzo L; Antoniotti C; Ambrosini M; Piva VM; Nichetti F; Fassan M; Cremolini C; Lonardi S
Eur J Cancer; 2023 Dec; 195():113396. PubMed ID: 37924647
[TBL] [Abstract] [Full Text] [Related]
10. The Role of microRNAs in Regulating cancer Cell Response to Oxaliplatin-Containing Regimens.
Tavakoli Pirzaman A; Ebrahimzadeh Pirshahid M; Babajani B; Rahmati A; Niknezhad S; Hosseinzadeh R; Taheri M; Ebrahimi-Zadeh F; Doostmohamadian S; Kazemi S
Technol Cancer Res Treat; 2023; 22():15330338231206003. PubMed ID: 37849311
[TBL] [Abstract] [Full Text] [Related]
11. TRIP6 disrupts tight junctions to promote metastasis and drug resistance and is a therapeutic target in colorectal cancer.
Gou H; Wong CC; Chen H; Shang H; Su H; Zhai J; Liu W; Liu W; Sun D; Wang X; Yu J
Cancer Lett; 2023 Dec; 578():216438. PubMed ID: 37827326
[TBL] [Abstract] [Full Text] [Related]
12. Mutation Profile via Next-Generation Sequencing in Patients with colorectal Adenocarcinoma and Its Clinicopathological Correlation.
Osman S; Kahraman Çetin N; Erdoğdu İH; Meteoğlu İ
Turk J Gastroenterol; 2023 Nov; 34(11):1124-1133. PubMed ID: 37737217
[TBL] [Abstract] [Full Text] [Related]
13. Cholesterol biogenesis is a pten-dependent actionable node for the treatment of endocrine therapy-refractory cancers.
Kaysudu I; Gungul TB; Atici S; Yilmaz S; Bayram E; Guven G; Cizmecioglu NT; Sahin O; Yesiloz G; Haznedaroglu BZ; Cizmecioglu O
Cancer Sci; 2023 Nov; 114(11):4365-4375. PubMed ID: 37706278
[TBL] [Abstract] [Full Text] [Related]
14. Rebound increase in microRNA levels at the end of 5-FU-based therapy in colorectal cancer patients.
Badr D; Fouad MA; Hussein M; Salem S; Zekri A; Shouman S
Sci Rep; 2023 Aug; 13(1):14237. PubMed ID: 37648713
[TBL] [Abstract] [Full Text] [Related]
15. CRISPR-Cas9 based knockout of S100A8 in mammary epithelial cells enhances cell proliferation and triggers oncogenic transformation via the PI3K-Akt pathway: Insights from a deep proteomic analysis.
Singh P; Ali SA; Kumar S; Mohanty AK
J Proteomics; 2023 Sep; 288():104981. PubMed ID: 37544501
[TBL] [Abstract] [Full Text] [Related]
16. Case Series of Men with the Germline APC I1307K variant and treatment-Emergent Neuroendocrine Prostate cancer.
Economides MP; Nakazawa M; Lee JW; Li X; Hollifield L; Chambers R; Sarfaty M; Goldberg JD; Antonarakis ES; Wise DR
Clin Genitourin Cancer; 2024 Feb; 22(1):e31-e37.e1. PubMed ID: 37482523
[TBL] [Abstract] [Full Text] [Related]
17. Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
Tassone P; Di Martino MT; Arbitrio M; Fiorillo L; Staropoli N; Ciliberto D; Cordua A; Scionti F; Bertucci B; Salvino A; Lopreiato M; Thunarf F; Cuomo O; Zito MC; De Fina MR; Brescia A; Gualtieri S; Riillo C; Manti F; Caracciolo D; Barbieri V; Di Paola ED; Di Francesco AE; Tagliaferri P
J Hematol Oncol; 2023 Jun; 16(1):68. PubMed ID: 37365583
[TBL] [Abstract] [Full Text] [Related]
18. The mechanism investigation of mutation genes in liver and lung metastasis of colorectal cancer by using NGS technique.
Liu K; Cui Y; Li H; Mi J; Wang H; Zhuang Y; Tang L; Liu J; Tian C; Zhang Z; Zhou J; Shi H; Tian X; Liu P
Crit Rev Oncol Hematol; 2023 Aug; 188():104057. PubMed ID: 37328085
[TBL] [Abstract] [Full Text] [Related]
19. Berberine Inhibited Growth and Migration of Human Colon cancer Cell Lines by Increasing Phosphatase and Tensin and Inhibiting Aquaporins 1, 3 and 5 Expressions.
Tarawneh N; Hamadneh L; Abu-Irmaileh B; Shraideh Z; Bustanji Y; Abdalla S
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175233
[No Abstract] [Full Text] [Related]
20. Metformin and thymoquinone co-treatment enhance 5-fluorouracil cytotoxicity by suppressing the PI3K/mTOR/HIF1α pathway and increasing oxidative stress in colon cancer cells.
Farrash WF; Aslam A; Almaimani R; Minshawi F; Almasmoum H; Alsaegh A; Iqbal MS; Tabassum A; Elzubier ME; El-Readi MZ; Mahbub AA; Idris S; Refaat B
Biofactors; 2023; 49(4):831-848. PubMed ID: 36929658
[TBL] [Abstract] [Full Text] [Related]
[Next]
